Nintedanib for telangiectasia, hereditary hemorrhagic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Jul 2021: Trial registered, NCT04976036
  2. 5 May 2022: Trial started, NCT04976036

The trials

NCT04976036: Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients

State
Under way
Phase
Phase 2
People
48 planned
Started
5 May 2022
Primary completion
Dec 2026
Arms
Nintedanib
Results
None posted
  1. 26 Jul 2021: Trial registered
  2. 5 May 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Ofev component nintedanib, Vargatef.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.